齐普罗夫洛克萨诱导的白细胞结晶性血管炎
André Cabrita1, Pedro Lisboa Gonçalves2, Catarina A Marques1
1Cardiology Department, Unidade Local De Saúde São João, Porto, PRT.
Cureus
|March 10, 2025
概括
常见的抗生素西普罗夫洛克萨很少会导致白细胞结晶性血管炎 (LCV). 这份病例报告强调了一名患者在停止服用药物后迅速康复,表现出罕见的不良反应.
科学领域:
- 药理学 药理学是指药理学的学科.
- 皮肤病学 皮肤病学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 齐普罗夫洛克萨是一种经常被处方的诺基诺抗生素,用于实证治疗各种感染.
- 与西普洛素相关的不良药物反应可以从轻度到严重程度,需要仔细监测.
- 白细胞结晶性血管炎 (LCV) 是西普洛素治疗的潜在,尽管罕见的不良影响.
研究的目的:
- 报告一种罕见的药物诱导的白细胞结晶性血管炎 (LCV) 病例,该病例是西普罗夫洛克萨的次要病例.
- 突出临床表现,诊断过程和成功管理西普洛素诱导的LCV.
- 强调在对皮肤病变的差异诊断中考虑药物诱导血管炎的重要性.
主要方法:
- 本文介绍了一个51岁的女性患者的案例研究,该患者被诊断患有白炎.
- 详细介绍了临床表现,包括皮肤活检在内的诊断工作以及治疗过程.
- 包括自身免疫性疾病在内的差异性诊断被系统地排除在外.
主要成果:
- 患者在开始服用西普罗夫洛克萨后一天内出现了特征性的皮肤血管病变.
- 皮肤活检证实了白细胞结晶性血管炎 (LCV) 的诊断.
- 停止服用西普罗夫洛克萨导致症状在五天内迅速消失,不需要使用皮质类固醇.
结论:
- 普洛素可以诱导白细胞结晶性血管炎 (LCV) 作为一种罕见的药物不良反应.
- 迅速识别和停止侵扰抗生素对于成功管理至关重要.
- 这一案例强调了彻底药物史的重要性,并考虑皮肤血管炎的阳性致病原因.
相关概念视频
Disorders of Leukocytes
825
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
825
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107


